MetLife Inc. (MET) Shares Sold by Ngam Advisors L.P.
Ngam Advisors L.P. cut its position in MetLife Inc. (NYSE:MET) by 15.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 335,059 shares of the company’s stock after selling 59,270 shares during the period. Ngam Advisors L.P.’s holdings in MetLife were worth $14,886,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the company. Commonwealth Bank of Australia increased its stake in shares of MetLife by 6.1% in the second quarter. Commonwealth Bank of Australia now owns 212,847 shares of the company’s stock valued at $8,480,000 after buying an additional 12,150 shares during the period. Deprince Race & Zollo Inc. increased its stake in shares of MetLife by 6.7% in the second quarter. Deprince Race & Zollo Inc. now owns 722,124 shares of the company’s stock valued at $28,762,000 after buying an additional 45,507 shares during the period. Hermes Investment Management Ltd. increased its stake in shares of MetLife by 12.3% in the second quarter. Hermes Investment Management Ltd. now owns 393,115 shares of the company’s stock valued at $15,658,000 after buying an additional 43,100 shares during the period. Douglas Lane & Associates LLC increased its stake in shares of MetLife by 4.6% in the second quarter. Douglas Lane & Associates LLC now owns 1,150,985 shares of the company’s stock valued at $45,844,000 after buying an additional 50,215 shares during the period. Finally, Bridgeway Capital Management Inc. increased its stake in shares of MetLife by 6.2% in the second quarter. Bridgeway Capital Management Inc. now owns 628,134 shares of the company’s stock valued at $25,019,000 after buying an additional 36,600 shares during the period. Institutional investors and hedge funds own 74.19% of the company’s stock.
MetLife Inc. (NYSE:MET) traded up 0.50% during mid-day trading on Tuesday, hitting $54.65. The company had a trading volume of 1,478,669 shares. The firm’s 50 day moving average is $49.69 and its 200 day moving average is $44.47. The company has a market capitalization of $60.07 billion, a price-to-earnings ratio of 16.79 and a beta of 1.66. MetLife Inc. has a 52 week low of $35.00 and a 52 week high of $55.49.
MetLife (NYSE:MET) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $1.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.04. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $17.03 billion. MetLife had a return on equity of 6.99% and a net margin of 5.58%. The company’s revenue for the quarter was down 99.9% on a year-over-year basis. During the same period last year, the business posted $0.62 EPS. On average, equities research analysts predict that MetLife Inc. will post $4.63 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 13th. Stockholders of record on Monday, November 7th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, November 3rd. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.94%. MetLife’s dividend payout ratio (DPR) is currently 49.23%.
WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of international copyright and trademark laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/29/metlife-inc-met-shares-sold-by-ngam-advisors-l-p.html.
Several equities research analysts recently issued reports on MET shares. TheStreet downgraded MetLife from a “buy” rating to a “hold” rating in a report on Wednesday, August 24th. FBR & Co upped their price target on MetLife from $51.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, August 29th. Argus reiterated a “buy” rating and set a $54.00 price target on shares of MetLife in a report on Wednesday, September 7th. Wells Fargo & Co. reiterated an “outperform” rating on shares of MetLife in a report on Friday, September 23rd. Finally, Credit Suisse Group AG started coverage on MetLife in a report on Friday, October 7th. They set a “neutral” rating and a $51.00 price target for the company. One analyst has rated the stock with a sell rating, five have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $51.35.
In related news, EVP Maria R. Morris sold 2,200 shares of MetLife stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $47.33, for a total transaction of $104,126.00. Following the transaction, the executive vice president now directly owns 109,809 shares in the company, valued at $5,197,259.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Frans Hijkoop sold 56,250 shares of MetLife stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $51.48, for a total value of $2,895,750.00. Following the transaction, the executive vice president now owns 111,813 shares in the company, valued at $5,756,133.24. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.
MetLife Company Profile
MetLife, Inc (MetLife) is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America (collectively, the Americas); Asia, and Europe, the Middle East and Africa (EMEA).
Receive News & Stock Ratings for MetLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife Inc. and related stocks with our FREE daily email newsletter.